Recruiting
Phase 1

Empasiprubart

Sponsor:

argenx

Code:

NCT07610564

Conditions

Multifocal Motor Neuropathy (MMN)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Empasiprubart IV

Study Details

Brief summary:

The main purpose of the study is to evaluate empasiprubart use in adults living with Multifocal Motor Neuropathy (MMN). The researchers will evaluate the effect of empasiprubart on the thickness of the nerves, muscle strength, movement, and on the potential improvement of grip strength of the participants in handling objects.

The study consists of an open-label treatment period where all participants will receive empasiprubart intravenously (IV). After the last dose of empasiprubart participants will enter a safety follow-up period for up to 15 months.

The total study duration for each participant will be approximately 29 months.

More information can be found here: clinicaltrials.argenx.com/empasound

Conditions

Multifocal Motor Neuropathy (MMN)

Study ID

NCT07610564

Start date

Jul 27, 2026

Status verified date

Sep, 2026

Completion date

Apr 1, 2030

Anticipated

Primary completion date

Feb 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Is at least 18 years old
  • Diagnosed with MMN
  • Has an MMN-RODS centile score of ≤90
  • Has confirmed nerve thickening in at least 1 nerve per ultrasound measurement

Exclusion Criteria:

  • Besides the indication under study, known autoimmune disease or any medical condition that, in the investigator's opinion, would interfere with an accurate assessment of clinical symptoms of MMN or puts the participant at undue risk.

Study Design

Enrollment

60 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Empasiprubart IV

Participants receive empasiprubart IV

Interventions

Empasiprubart IV

Intravenous infusions of empasiprubart

Primary outcome measure

  • Change from baseline in nerve CSA at week 24 as measured by ultrasound imaging of the median nerve and brachial plexus (individual nerves and average sum score) [ Time Frame: Up to 48 weeks ]

Central Contacts and Locations

Central contacts

Locations

Yale University School of Medicine

Recruiting

New Haven, Connecticut, United States, 65103221

Contacts

More Information

Sponsor

argenx

Last update posted

Nov 16, 2026

Last verified

Sep, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by argenx on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.